Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by lscfaon Feb 19, 2024 3:27pm
85 Views
Post# 35887858

RE:RE:RE:RE:CZO down 5.7% last week, market up 1.6%

RE:RE:RE:RE:CZO down 5.7% last week, market up 1.6%

 

 

Revenues

R&D

Salaries

Consulting

B of D comp

Legal

Q3 23

2,618,973

584,665

325,000

120,000

229,000

921,000

Q2 23

1,868,758

926,775

493,000

200,000

196,000

232,000

Q1 23

3,494,811

573,687

361,000

120,000

271,000

343,000

Q4 22

3,322,214

575,211

308,000

120,000

103,000

7,000

Q3 22

3,845,370

314,250

286,000

120,000

120,000

0

Q2 22

5,500,399

543,924

316,000

200,000

75,000

17,000

Q1 22

6,171,624

355,281

217,000

120,000

120,000

3,000

 

<< Previous
Bullboard Posts
Next >>